478-84-2

Usage

Safety Profile

Poison by intraperitoneal and intravenous routes. Experimental teratogenic and reproductive effects. Human systemic effects by ingestion: ddation of the arteries or veins. Many lysergic acid derivatives have central nervous system effects. When heated to decomposition it emits very toxic fumes such as Brand NOx. See other lysergic acid derivatives.

InChI:InChI=1/C20H24BrN3O/c1-4-24(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(21)22-16)10-17(14)23(3)11-12/h6-9,12,17,22H,4-5,10-11H2,1-3H3/t12-,17-/m1/s1

Upstream product

• 50-37-3 lysergide 

Downstream Products

• 50484-98-5 2-bromo-1,6-dimethyl-9,10-didehydro-ergoline-8β-carboxylic acid diethylamide 

Relevant academic research and scientific papers

Process for brominating ergot alkaloids

The present invention provides an improved process for the production of a compound of formula I STR1 wherein R1 is carboxyl, alkoxy(C1-5)carbonyl, amido, alkyl(C1-5)amido, di(alkyl(C1-5)amido or an amido radical of formula II STR2 wherein Ra is alkyl(C1-4), Rb is alkyl(C1-4) or benzyl, and R2 is hydrogen or alkyl(C1-4), and either R3 is hydrogen and R4 is hydrogen or alkoxy(C1-4) or R3 and R4 together are a single bond, characterized in that a compound of formula III STR3 wherein R1 to R4 are as defined above, is brominated with a bromine complex of 3-bromo-6-chloro-2-methyl-imidazo[1,2-b]pyridazine.

BROMINATION OF α-ERGOCRYPTINE AND OTHER ERGOT ALKALOIDS WITH 3-BROMO-6-CHLORO-2-METHYLIMIDAZO/1,2-b/PYRIDAZINE-BROMINE COMPLEX AS A NEW BROMINATING AGENT

A new and improved bromination of α-ergocryptine and some other ergot alkaloids of the type 1, 2 and 3 using 3-bromo-6-chloro-2-methylimidazo/1,2-b/pyridazine-bromine complex (5) as a new brominating agent, to give purified 2-bromo derivatives in yields up to 81percent, is described.